Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Tuesday 09 August, 2005

XTL Biopharm Ltd

HepeX-B Phase 2 end dosing

XTL Biopharmaceuticals Ltd
09 August 2005


         XTLbio announces the end of patient dosing in HepeX-B(TM) hepatitis B
                                    Phase 2 trial

       XTLbio also announces the accelerated transition of HepeX-B program to
                                Cubist Pharmaceuticals

Rehovot, Israel, 9 August 2005: XTL Biopharmaceuticals Ltd. (LSE:XTL) ('XTLbio')
announced today that XTLbio and Cubist Pharmaceuticals (NASDAQ: CBST) have ended
patient dosing in the second of two Phase 2 hepatitis B clinical trials of
HepeX-B. Cubist plans to review data from this trial with the FDA as part of a
discussion of design elements of a Phase 3 trial. A Data Safety Monitoring Board
recently reviewed safety data from all patients in the Phase 2 trial and no
concerns were raised.

XTLbio also announced that the transition of HepeX-B development activities from
XTLbio to Cubist was completed, and that, accordingly, Cubist will not make
collaborative support payments which would otherwise have been due to XTLbio in
2005 of $1 million. The collaborative support payments were established to cover
XTLbio overhead associated with managing the HepeX-B program. Cubist will
reimburse XTLbio for all direct costs associated with the program incurred at
the request of Cubist.

'I am very pleased with the completion of transition of HepeX-B development
activities to Cubist' said Michael Weiss, Chairman of XTLbio, who continued,
'with all further development and commercialization activities of HepeX-B now in
the hands of our partner Cubist, we can focus all of XTLbio's current resources
on our internal hepatitis C programs.'

Contacts:

XTLbio

Jonathan Burgin, Chief Financial Officer Tel: +972 8 930 4440

Notes to Editors

XTL Biopharmaceuticals Ltd. (XTLbio) is a biopharmaceutical company developing
drugs against hepatitis. Established in 1993, XTLbio became a public company in
2000 and its ordinary shares are listed on the Official List of the UK Listing
Authority and are traded on the London Stock Exchange under the symbol XTL and
in the Tel Aviv Stock Exchange, Israel.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
                                                          

a d v e r t i s e m e n t